本刊去年第10期36页“新药评介”栏曾发表“雷公藤片”一文。按雷公藤片为雷公藤的提取物片剂,与中国医学科学院皮肤病研究所、南京药学院等共同研制的雷公藤总甙(T-Ⅱ),差异较大。为避免引起混淆,影响临床用药安全,特将本文发表。又,本刊去年第10期37页左7行应将“南京药学院药厂”删去。 Last issue of the 10th issue of the journal last year was published on the 36 pages of the “New Drug Reviews” column. The Tripterygium wilfordii extract (T-II), which is based on Tripterygium wilfordii extract tablets, and the Institute of Dermatology of the Chinese Academy of Medical Sciences and the Nanjing Pharmaceutical Institute, is quite different. In order to avoid confusion and affect the safety of clinical medications, this article will be published. Also, on the 37th page, the 7th line of the last issue of the 10th issue of the journal should be deleted from the “Nanjing Pharmaceutical College”.